Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model

PURPOSE: Ceftriaxone elimination occurs through breast cancer resistance transporter (BCRP) and multidrug resistance-associated protein 2 (MRP-2) which are expressed on the canalicular membrane of hepatocytes. Eltrombopag, a thrombopoetin receptor agonist used in the treatment of immune thrombocytop...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Daniel Valente Neves (Egilea), Carolina Pinto Vieira (Egilea), Adriana Rocha (Egilea), Vera Lucia Lanchote (Egilea)
Formatua: Liburua
Argitaratua: Frontiers Media S.A., 2018-06-01T00:00:00Z.
Gaiak:
Sarrera elektronikoa:Connect to this object online.
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

Connect to this object online.

3rd Floor Main Library

Aleari buruzko argibideak 3rd Floor Main Library
Sailkapena: A1234.567
Alea 1 Eskuragarri